Take Action
Individual diagnoses change lives. Systemic change saves them. The campaigns on this page are working toward both.
Take Action
Individual diagnoses change lives. Systemic change saves them. The campaigns on this page are working toward both.
The advocacy campaigns listed here target the structural barriers that prevent women from receiving a correct Lipedema diagnosis and appropriate care. Current focus areas include GP training, NHS and HSE treatment funding, and implementation of ICD-11 in insurance and health system billing. These campaigns are coordinated, achievable, and supported by a growing international evidence base.
The policy landscape for Lipedema has improved over the past decade. The UK has a NICE guideline. The WHO has added Lipedema to ICD-11. The US has a Standard of Care. The 2024 Lipedema World Alliance Delphi Consensus represents the clearest international consensus on what good care should look like.
But guidelines and recognition documents do not translate automatically into what happens to women in consulting rooms, treatment waiting rooms, and insurance appeal processes. The gap between what the evidence says and what patients experience remains significant, and it remains so in every country.
Campaigns are the mechanism for closing that gap.
Individual advocacy matters. A woman who writes to her MP, who challenges her insurer, who hands her GP a printout of the NICE guideline: she changes what happens to her. Sometimes she changes what happens to the next patient that doctor sees.
But individual advocacy is exhausting, and it should not be necessary. Women who are in pain, who are managing a chronic condition, who have already fought for years just to be believed, should not have to also fight for the systems around them to function correctly.
Campaigns change the system so that individuals do not have to fight every battle alone. When a medical school adds Lipedema to its curriculum, every GP who trains there arrives knowing what the condition is. When a health service updates its funding criteria, women do not have to appeal individually.
The campaigns on this page are designed to produce exactly that kind of systemic change.
The most common single point of failure in Lipedema care is the GP appointment. Women with Lipedema typically see a GP with obvious symptoms, and are dismissed, blamed for their weight, or simply not recognised.
This is not the fault of individual GPs. They are working with the training they received, and most medical schools have not included Lipedema in their curricula. A condition that affects 6-11% of women is not being taught to the doctors who will see all of them.
The campaign asks medical schools and postgraduate training bodies to include Lipedema in their syllabuses, and asks health services to include it in GP continuing professional development. The ask is specific and achievable.
In the UK, NICE NG203 (2022) provides clear guidance that Lipedema should be recognised and managed within the NHS. The guidance includes conservative management (compression therapy, lymphoedema treatment) and acknowledges surgical options for appropriate patients.
In practice, implementation is inconsistent. Women in some NHS trust areas can access funded treatment. Women in others cannot. In Ireland, the position is even less defined.
The campaign asks NHS England, NHS Scotland, and the HSE to publish clear, consistent funding criteria for Lipedema treatment and to monitor implementation across services.
ICD-11 includes Lipedema as a distinct diagnosis under code FA00. Countries adopting ICD-11 are doing so on a rolling basis. In theory, this means Lipedema is a billable, codeable condition that insurers must engage with.
In practice, many insurers continue to classify Lipedema treatment as cosmetic or exclude it from coverage, often because their policy language has not been updated to reflect ICD-11 adoption.
The campaign asks health system administrators and insurers, by country, to confirm that Lipedema is coded correctly under ICD-11 and that coverage determinations reflect that coding.
Each campaign has specific actions you can take, from social media shares to letters to decision-makers. The template letters section has ready-to-use letters for each of the current campaigns. The policy tracker gives you the country-specific context you need to make those letters effective.
Start with one action. Send one letter. Share one post. The cumulative effect of many individual actions is what makes campaigns move.
Evidence rating: Strong for the systemic gaps that these campaigns address. The 2025 progress review in PMC documents the persistent implementation gap between Lipedema guidelines and patient experience. The 2024 Lipedema World Alliance Delphi Consensus, drawn from an international expert panel, identified GP education, treatment funding, and ICD-11 implementation as the highest-priority areas for systemic change.
Patient-driven advocacy has a documented track record in Lipedema: the NICE NG203 guideline and ICD-11 recognition were both influenced by sustained advocacy from patient organisations and individuals. The research base supporting these campaigns is strong and growing.
You do not need to run a campaign to support one. Sharing a campaign on social media, writing to your elected representative, or simply talking about Lipedema in your own circles all contribute to the visibility that drives policy change. Every action, however small, adds to the collective pressure that makes systemic change possible.